During the past year we have had excellent results in treating chronic discoid lupus erythematosus with quinacrine (Atabrine) hydrochloride. As the great number of solar dermatoses begin each spring we had planned to see what effect the drug would have in these cases, since Page1 had shown the time necessary to produce a minimum erythema dose of ultraviolet light to be increased from 6 to 24 seconds in one patient receiving quinacrine for 10 days; another patient receiving the drug for a similar time had shown an increase from 20 to 36 seconds. Page1 felt that much of the effect of quinacrine in lupus erythematosus was due to the pigmentation of the skin decreasing the photosensitive reaction, which is recognized as a potent factor in this disease. He did note that this pigmentation did not explain the beneficial effects in systemic manifestations of the disease. Sulzberger and
WOODBURNE AR, PHILPOTT OS, PHILPOTT JA. QUINACRINE (ATABRINE) IN TREATMENT OF SOLAR DERMATOSES. AMA Arch Derm Syphilol. 1954;70(1):116–118. doi:10.1001/archderm.1954.01540190118012
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: